95 results on '"Gercheva L"'
Search Results
2. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
3. PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A
4. P1138: COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL
5. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B
6. Efficacy, safety, and pharmacokinetics results of a phase II, double-blinded, randomized, cross-over study with Biostate® in subjects with hemophilia A (the SWIFT-HA Study): PO-WE-063
7. Regional differences in baseline patient-reported outcomes in a randomized, controlled, prospective trial of secondary prophylaxis VS on-demand treatment in patients with severe hemophilia A: PO-WE-058
8. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine®, a high-purity factor IX concentrate, in patients with severe haemophilia B
9. Significantly higher and more rapid cytogenetic and molecular responses can be achieved in pre-treated chronic phase CML patients with high doses of Imatinib as induction therapy (800 mg/day, 6 months) - final results of a Phase III CELSG CML11 “ISTAHIT” TRIAL: V278
10. An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B
11. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols®) with a 6-month follow up in previously treated patients with severe haemophilia B
12. High Dose Imatinib (800mg/day) improves Cytogenetic and Molecular Remissions in pretreated Ph+/BCR-ABL+ CML Patients in Chronic Phase; Results from the CELSG CML 11 “ISTAHIT” Phase III Study: V57
13. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia
14. Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma
15. PB2181 THE ROLE OF 18F-FDG PET/CT IN THE INITIAL DIAGNOSIS AND STAGING OF PATIENTS WITH MULTIPLE MYELOMA
16. PB1912 EFFICACY AND SAFETY OF RITUXIMAB BIOSIMILAR TRUXIMA IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND NON-HODGKIN'S LYMPHOMAS
17. PF667 THE ROLE OF HEPCIDIN AND DYSREGULATED IRON HOMEOSTASIS IN THE PATHOGENESIS OF ANEMIA IN MYELOFIBROSIS
18. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study
19. PK-guided personalized prophylaxis with Nuwiq®(human-cl rhFVIII) in adults with severe haemophilia A
20. 1073P - Prognostic factors influencing outcome after therapy with brentuximab vedotin in patients with relapsed or refractory Hodgkin’s lymphoma
21. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma
22. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
23. Bendamustine Versus Chlorambucil In Treatment- Naive Patients With Chronic Lymphocytic Leukemia: Updated Results of An International Phase Iii Study
24. PK-guided personalized prophylaxis with Nuwiq® (human-cl rh FVIII) in adults with severe haemophilia A.
25. Health Care Resource Utilization (HCRU) In Hospitalized Febrile Neutropenia (FN) Patients Treated With Chemotherapy For Solid Tumors (ST) And Hematological Malignancies (HM) In Bulgaria
26. P-138 New approaches for risk assessment of patients with myelodysplastic syndrome
27. High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients - final analysis of a randomized, multicenter, phase III trial
28. 97 Clinical characteristics and survival of MDS patients in Hematology Clinic, University Hospital, Varna. Reassessment according to WHO, IPSS, WPSS
29. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study
30. An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B
31. Application of Human Recombinant Granulocyte Coloni-Stimulating Factor (rHU-G-CSF) Onto Patients with Medicamentally and Radiately Provoked Neutropenia and Aplastic Anaemia
32. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia
33. A Pharmacokinetic Study of the Plasma-Derived Factor IX AlphaNine® and Its Comparison with the Recombinant Factor IX BeneFIX®, in Previously Treated Patients with Severe Hereditary Hemophilia B.
34. PCN238 - Health Care Resource Utilization (HCRU) In Hospitalized Febrile Neutropenia (FN) Patients Treated With Chemotherapy For Solid Tumors (ST) And Hematological Malignancies (HM) In Bulgaria
35. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
36. An open clinical study assessing the efficacy and safety of Factor IX Grifols®, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
37. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols®) with a 6-month follow up in previously treated patients with severe haemophilia B.
38. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
39. Experimental attempt to produce mRNA transfected dendritic cells derived from enriched CD34+ blood progenitor cells
40. Therapeutic results in patients with Hodgkin's lymphoma treated with brentuximab vedotin-bulgarian experience
41. Cytostatic therapy and blood antioxidants/prooxidants balance in acute myeloblastic leukemia patients
42. Development of Multiple Myeloma in 2 Patients with Chronic Pyelonephritis and Long-Term Hemodialysis Treatment.
43. A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia
44. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
45. Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
46. A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
47. Detection of EBV DNA in Non-Hodgkin Lymphoma Patients in Bulgaria.
48. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
49. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.
50. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.